{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=13", "query": { "intervention": "Arm 1- Dose Escalation", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 959, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:07:34.411Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07577661", "title": "Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Obstructive Sleep Apnea", "Sleep-disordered Breathing" ], "interventions": [ { "name": "Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy)", "type": "OTHER" }, { "name": "Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition", "type": "DEVICE" }, { "name": "Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition", "type": "DRUG" }, { "name": "Placebo; placebo comparator condition", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DEVICE", "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 24, "start_date": "2026-09-01", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-11-15T12:07:34.411Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07577661" }, { "nct_id": "NCT00086580", "title": "Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B-Cell Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "FluCAM [Fludara + Campath]", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 335, "start_date": "2004-07", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2014-03-13", "last_synced_at": "2026-11-15T12:07:34.411Z", "location_count": 1, "location_summary": "Fort Myers, Florida", "locations": [ { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00086580" }, { "nct_id": "NCT07206056", "title": "An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Progressive Metastatic Castrate Resistant Prostate Cancer" ], "interventions": [ { "name": "Tulmimetostat DL1 QD", "type": "DRUG" }, { "name": "Tulmimetostat DL2 QD", "type": "DRUG" }, { "name": "Tulmimetostat DL3 QD", "type": "DRUG" }, { "name": "Tulmimetostat Doses 1 or 2 QD", "type": "DRUG" }, { "name": "Tulmimetostat RP2D QD", "type": "DRUG" }, { "name": "JSB462 Dose 1 QD", "type": "DRUG" }, { "name": "JSB462 Dose 2 QD", "type": "DRUG" }, { "name": "JSB462 QD", "type": "DRUG" }, { "name": "Standard of Care (SoC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 188, "start_date": "2025-10-15", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-15T12:07:34.411Z", "location_count": 8, "location_summary": "Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07206056" }, { "nct_id": "NCT04676178", "title": "A Study of PRA023 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PRA023", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 69, "start_date": "2020-12-15", "completion_date": "2021-09-23", "has_results": false, "last_update_posted_date": "2024-01-17", "last_synced_at": "2026-11-15T12:07:34.411Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04676178" }, { "nct_id": "NCT02509052", "title": "Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2015-12-02", "completion_date": "2022-06-09", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-11-15T12:07:34.411Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02509052" }, { "nct_id": "NCT01292655", "title": "Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "BMS-906024", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2011-03-03", "completion_date": "2017-06-22", "has_results": false, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-11-15T12:07:34.411Z", "location_count": 6, "location_summary": "Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01292655" }, { "nct_id": "NCT00594984", "title": "Phase I/II Combination With Irinotecan- Erbitux", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer (MCRC)" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Brivanib", "type": "DRUG" }, { "name": "Brivanib Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2008-05", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-11-15T12:07:34.411Z", "location_count": 4, "location_summary": "Los Angeles, California • Louisville, Kentucky • St Louis, Missouri", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00594984" }, { "nct_id": "NCT00834184", "title": "Safety and PK of Nikkomycin Z in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "nikkomycin Z", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 32, "start_date": "2008-10", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2020-11-23", "last_synced_at": "2026-11-15T12:07:34.411Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00834184" }, { "nct_id": "NCT01001221", "title": "Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms, Malignant" ], "interventions": [ { "name": "cabazitaxel", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2009-11", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-09-11", "last_synced_at": "2026-11-15T12:07:34.411Z", "location_count": 4, "location_summary": "Detroit, Michigan • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01001221" }, { "nct_id": "NCT05896228", "title": "Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma", "Relapsed Multiple Myeloma" ], "interventions": [ { "name": "Iberdomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Benjamin T Diamond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2024-02-20", "completion_date": "2031-03-01", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-11-15T12:07:34.411Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05896228" } ] }